title: miR-194 is a negative regulator of GEF-H1 pathway in melanoma.
abstract: The incidence and associated mortality of melanoma continues to increase worldwide. At present, there is no curative therapy for advanced stage of melanoma. It is necessary to find new indicators of prognosis and therapeutic targets. Increasing evidence shows that miRNA can provide potential candidate biomarkers for melanoma and therapeutic targets. GEF-H1, a regulator of RhoA, as oncogenic driver in melanoma, promotes the growth and invasion of melanoma. miR-194 is a tumor-suppressor gene in multiple tumors, such as bladder and non-small cell lung cancer, and clear cell renal cell carcinoma. In the present study, we demonstrated that GEF-H1 serves as target of miR-194. Overexpression of miR-194 downregulates the GEF-H1/RhoA pathway, inhibits melanoma cancer cell proliferation and metastasis. Furthermore, miR-194 expression is negatively associated with tumor-node-metastasis (TNM) stages. Briefly, our findings provided new theoretical basis for melanoma treatment.
authors: Reconstructive and Plastic Surgery, The General Hospital of Shenyang Military Region, Shenhe, Shenyang, Liaoning 110016, P.R. China.
authors: Bingyu
authors: B
authors: Guo
authors: Reconstructive and Plastic Surgery, The General Hospital of Shenyang Military Region, Shenhe, Shenyang, Liaoning 110016, P.R. China.
authors: Qiang
authors: Q
authors: Hui
authors: Reconstructive and Plastic Surgery, The General Hospital of Shenyang Military Region, Shenhe, Shenyang, Liaoning 110016, P.R. China.
authors: Yu
authors: Y
authors: Zhang
authors: Reconstructive and Plastic Surgery, The General Hospital of Shenyang Military Region, Shenhe, Shenyang, Liaoning 110016, P.R. China.
authors: Peng
authors: P
authors: Chang
authors: Reconstructive and Plastic Surgery, The General Hospital of Shenyang Military Region, Shenhe, Shenyang, Liaoning 110016, P.R. China.
authors: Kai
authors: K
authors: Tao
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics*; D063646:Carcinogenesis / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation / Q000235:genetics; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis / Q000235:genetics / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000235:genetics* / Q000473:pathology; D035683:MicroRNAs / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D015398:Signal Transduction / Q000235:genetics; D014157:Transcription Factors / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C554846:MIRN194 microRNA, human; D035683:MicroRNAs; C480633:SLC2A4RG protein, human; D014157:Transcription Factors